EN
DE 
NL 
FR 
ES 
IT 
CS 
PL Cannabinoid · Pharmaceutical
Nabiximols (Sativex) is a pharmaceutical 1:1 THC:CBD botanical cannabis extract, given as an oromucosal spray and approved for MS spasticity.
Where it fits
Nabiximols derives from Cannabis extract. See the Synthetic & altered cannabinoids index for how it relates to the rest of the family.
What the research shows
Nabiximols has approved (many countries)-level evidence; see the class index and related compounds for cited studies.
Standardized 1:1 THC:CBD Oromucosal Formulation and MS Spasticity Trials
Nabiximols (Sativex) is a standardized botanical extract formulated as an oromucosal spray delivering 2.7 mg Delta-9-THC and 2.5 mg CBD per 100 μL actuation. In a pivotal enriched-design randomized controlled trial of 241 patients with refractory multiple sclerosis (MS) spasticity, add-on nabiximols significantly improved spasticity Numeric Rating Scale scores compared with placebo (Novotna et al., 2011, European Journal of Neurology, PubMed PMID 21362108). Parallel-group randomized trials and pooled meta-analyses confirm clinically meaningful responder rates alongside common dose-related adverse events such as dizziness, fatigue, and oral mucosal irritation (Collin et al., 2010, Neurological Research, PubMed PMID 20307378; Wade et al., 2010, Multiple Sclerosis, PubMed PMID 20558502).
FAQ
What is the exact THC to CBD ratio in nabiximols (Sativex)?
Each 100 microliter spray actuation of nabiximols delivers a standardized near-1:1 ratio of 2.7 mg Delta-9-THC and 2.5 mg cannabidiol (CBD) extracted from defined Cannabis sativa chemotypes.
What medical condition is nabiximols approved to treat?
Nabiximols is approved in over 25 countries (including across Europe, the UK, and Canada) as an add-on prescription treatment for moderate to severe spasticity due to multiple sclerosis (MS) when first-line antispastic drugs are insufficient.
Is nabiximols psychoactive?
Yes. Because each spray contains 2.7 mg of Delta-9-THC, nabiximols can cause dose-dependent dizziness, somnolence, and mild intoxication, especially during initial dose titration.
Part of the NOIDS cannabinoids index. Educational reference, not medical advice.
English